<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>POTASSIUM CHLORIDE IN LACTATED RINGERS AND DEXTROSE- dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride and calcium chloride injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>Potassium Chloride in Lactated Ringer’s and<br>5% Dextrose Injection, USP<br>in Plastic Container <br>VIAFLEX Plus Container</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_inv-024955dd-5784-44a1-8c7f-cd3e51b6a111"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown below:</p>
<a name="id_f36ace2f-77c5-4f92-863d-ec2348f8eca7"></a><table border="single" width="599">
<caption><span>Table 1.</span></caption>
<col width="22.9%">
<col width="6.3%">
<col width="11.0%">
<col width="9.2%">
<col width="8.2%">
<col width="10.0%">
<col width="14.0%">
<col width="18.4%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>The chemical structure for Dextrose Hydrous, USP is shown below:<img alt="D-Glucose Monohydrate Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05f326e6-10e4-4ceb-8a23-f53c592f00b8&amp;name=14e57ddb-471a-4740-baef-451d53dccefe-01.jpg">
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="middle">Size<br>(mL)</td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top">Composition (g/L)</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="middle">
<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Osmolarity <br>(mOsmol/L) (calc.)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle">
<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>Dextrose Hydrous, <br>USP</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Sodium Chloride, USP (NaCl)</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Sodium Lactate, (C<span class="Sub">3</span>H<span class="Sub">5</span>NaO<span class="Sub">3</span>)</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Potassium Chloride, USP <br>(KCl)</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Calcium Chloride, <br>USP<br>(CaCl<span class="Sub">2-</span>2H<span class="Sub">2</span>O)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" valign="top">Potassium Chloride in<br>Lactated Ringer’s and 5%<br>Dextrose Injection,<br>USP</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" valign="top">mEq Potassium added</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mEq</td>
<td class="Botrule Rrule" align="center" valign="top">1000</td>
<td class="Botrule Rrule" align="center" valign="top">50</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3.1</td>
<td class="Botrule Rrule" align="center" valign="top">1.79</td>
<td class="Botrule Rrule" align="center" valign="top">0.2</td>
<td class="Botrule Rrule" align="center" valign="top">565</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<a name="id_4b32312d-c554-4dbb-a829-81bb27304182"></a><table border="single" width="538">
<caption><span>Table 2.</span></caption>
<col width="21.4%">
<col width="11.3%">
<col width="9.1%">
<col width="14.3%">
<col width="10.2%">
<col width="10.2%">
<col width="10.2%">
<col width="13.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">pH</td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top">Ionic Concentration (mEq/L)</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Caloric Content<br>(kcal/L)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Potassium Chloride in<br>Lactated Ringer’s and<br>5% Dextrose Injection,<br>USP</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Sodium</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">Potassium</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Calcium</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Chloride</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Lactate</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" valign="top">mEq Potassium added</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mEq</td>
<td class="Rrule" align="center" valign="top">5.0<br>(3.5to6.5)</td>
<td class="Rrule" align="center" valign="top">130</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">24</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">129</td>
<td class="Rrule" align="center" valign="top">28</td>
<td class="Botrule Rrule" align="center" valign="top">170</td>
</tr>
</tbody>
</table>
<p>The VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_inv-14f58e91-2359-4555-be4e-ac1604994cb8"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP have value as a source of water, electrolytes, and calories. It is capable of inducing <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> depending on the clinical condition of the patient.</p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP produce a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water, which requires the consumption of hydrogen cations.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_inv-8e180100-1be3-4cdf-b7af-ce11e3ed695b"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP are indicated as a source of water, electrolytes, and calories or as alkalinizing agents.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_inv-b83dd024-aa3c-4b44-9be3-9cb4ea289354"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">As for other calcium-containing infusion solutions, concomitant administration of ceftriaxone and Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is contraindicated in newborns (≤ 28 days of age), even if separate infusion lines are used (risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream). </p>
<p>In patients older than 28 days (including adults), ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP, through the same infusion line (e.g., via Y-connector).  If the same infusion line is used for sequential administration, the line must be thoroughly <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> between infusions with a compatible fluid. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sodium lactate. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_inv-f0fb7966-12fd-4c3f-bdca-05c4d9d8f275"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is not for use for the treatment of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should not be administered simultaneously with citrate anticoagulated/preserved blood through the same administration set because of the likelihood of coagulation. </p>
<p>The infusion must be stopped immediately if any signs or symptoms of a suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> develop.  Appropriate therapeutic countermeasures must be instituted as clinically indicated.</p>
<p>Solutions containing dextrose should be used with caution, if at all, in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to corn or corn products. </p>
<p>Depending on the volume and rate of infusion, the intravenous administration of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, congested states,  <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> or acid-base imbalance.  The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> is directly proportional to the electrolyte concentrations of the injection.</p>
<p>Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be administered with particular caution, if at all, to patients with conditions predisposing to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (such as severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or adrenocortical insufficiency, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or extensive tissue injury or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>), in patients with cardiac disease, and in patients treated with products that increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be administered with particular caution, if at all, to patients with <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> or at risk for <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>.  Because lactate is metabolized to <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, administration may result in, or worsen, <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be administered with particular caution, if at all, to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, or conditions that may cause sodium and/or potassium retention, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>, or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
<p>Potassium salts should never be administered by IV push.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_inv-3e4f0243-f82e-4195-a64c-1715a41f6fdc"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Do not connect flexible plastic containers in series in order to avoid <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to possible residual air contained in the primary container. </p>
<p>Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> if the residual air in the container is not fully evacuated prior to administration.  </p>
<p>Use of a vented intravenous administration set with the vent in the open position could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span>.  Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. </p>
<p>Lactate is a substrate for gluconeogenesis.  Administration of solutions containing dextrose and lactate should be used with caution in patients with impaired glucose tolerance and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, as it may result in <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> has been implicated in increasing cerebral ischemic <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> and impairing recovery after acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic strokes</span>.  Caution is recommended in using dextrose-containing solutions in such patients. </p>
<p>Early <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has been associated with poor outcomes in patients with severe <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>.  Dextrose-containing solutions should, therefore, be used with caution in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, in particular during the first 24 hours following the <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. </p>
<p>If <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> occurs, the rate of dextrose administration should be reduced and/or insulin administered, or the insulin dose adjusted. </p>
<p>Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be administered with particular caution, if at all, to patients with conditions associated with increased lactate levels or impaired lactate utilization, such as severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.  </p>
<p>Hyperlactatemia (i.e., high lactate levels) can develop in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, since lactate metabolism may be impaired.  In addition Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP may not produce its alkalinizing action in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, since lactate metabolism may be impaired. </p>
<p>The osmolarity of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is 565 mOsmol/L (calc) for 20 mEq potassium added and 605 mOsmol/L (calc) for 40 mEq potassium added.  Administration of substantially hypertonic solutions may cause venous irritation, including <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>.  Hyperosmolar solutions should be administered with caution, if at all, to patients with hyperosmolar states. </p>
<p>Solutions containing calcium salts should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or conditions predisposing to hypercalemia, such as patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and granulomatous diseases associated with increased calcitriol synthesis such as <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, calcium <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculi</span> or history of such calculi.</p>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_inv-156043e6-5067-45a5-9e26-a3a1bd5e3e39"></a><a name="section-6.1"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP in pediatric patients have not been established by adequate and well-controlled studies. However, the use of potassium chloride injection in pediatric patients to treat <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">potassium deficiency</span> states when oral replacement therapy is not feasible is referenced in the medical literature.</p>
<p>In newborns, the risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> due to infusion of dextrose-containing solutions appears to be greater with lower birth weight.  In these patients, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and increased serum osmolarity have been associated with an increased risk of intraventricular <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>. </p>
<p>Lactate-containing solutions should be administered with particular caution to neonates and infants less than 6 months of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_inv-a75bb094-a963-4728-b6ad-30874ce390d3"></a><a name="section-6.2"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_3ddb2583-eef7-4a4b-b918-3101c856dd74"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ceftriaxone – see <a href="#i4i_contraindications_id_inv-b83dd024-aa3c-4b44-9be3-9cb4ea289354">CONTRAINDICATIONS</a></p>
<p>Caution is advised when administering Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP to patients treated with drugs that may increase the risk of sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, such as corticosteroids.  </p>
<p>Caution is advised when administering Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP to patients treated with drugs for which renal elimination is pH dependent.  Due to the alkalinizing action of lactate (formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>), Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP may interfere with the elimination of such drugs.<br></p>
<ul>
<li>Renal clearance of acidic drugs such as salicylates and barbiturates may be increased.</li>
<li>Renal clearance of alkaline drugs, such as sympathomimetics (e.g., ephedrine, pseudoephedrine) and dextroamphetamine (dexamphetamine) sulfate, may be decreased.<p class="First"></p>
</li>
</ul>
<p>Renal clearance of lithium may also be increased.  Caution is advised when administering Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP to patients treated with lithium.</p>
<p>Because of its potassium content, administration of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be avoided in patients treated with agents or products that can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> or increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.  Administration of potassium in patients treated with such medications can produce severe and potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.  </p>
<p>Caution is advised when administering Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP to patients treated with thiazide diuretics or vitamin D, as these can increase the risk of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ad02ac90-6415-4dcd-8c6c-835bd1b09d8a"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_0f239f4c-bf29-458e-9c64-f84d49fbb3fb"></a><a name="section-6.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_02eab85c-6139-4c7c-94c7-ce2ce2b3d0a5"></a><a name="section-6.4.1.1"></a><p></p>
<h4>Pregnancy Category C.</h4>
<p class="First">Animal reproduction studies have not been conducted with Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP. It is also not known whether Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_inv-27916574-c109-4936-a261-535f0eb59d2d"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential or studies to evaluate mutagenic potential have not been performed with Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP.  Studies to evaluate the possible impairment of fertility have not been performed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_03eb323e-7e75-478d-a155-0414b1af7474"></a><a name="section-6.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Studies have not been conducted to evaluate the effects of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP on labor and delivery.  Caution should be exercised when administering this drug during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_inv-b3ed4f54-2870-477b-b1d5-ae8353fcc146"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is administered to a nursing mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_inv-3427edc9-05ae-4881-ac1f-4b422d20187f"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3bdb0f7-81e8-4a9f-b1ef-e4c9bf9aa135"></a><a name="section-7.1"></a><p></p>
<h2>Post-Marketing Adverse Reactions</h2>
<p class="First">The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC).<br><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/infusion reactions, including anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, and the following manifestations: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> <br>General Disorders and Administration Site Conditions:<br>Infusion site reactions, including infusion site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, infusion site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, infusion site anesthesia (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a3a8518-74ce-4455-bb0c-90c589f3b1c0"></a><a name="section-7.2"></a><p></p>
<h2>Class Reactions</h2>
<ul>
<li>Other manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/infusion reactions: decreased heart rate, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">hypoesthesia oral</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span></li>
<li>Other infusion site reactions: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, infusion site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, infusion site <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, infusion site <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, infusion site burning</li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_46e36df7-e6dc-4a68-89dc-e72ea8cdb66a"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">An excessive volume or too high a rate of administration of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP may lead to fluid and sodium overload with a risk of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired.  </p>
<p>Excessive administration of lactate may lead to <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.  <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">Metabolic alkalosis</span> may be accompanied by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Excessive administration of potassium may lead to the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, especially in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>Excessive administration of calcium salts may lead to <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<p>Excessive administration of a dextrose-containing solution may lead to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, hyperosmolarity, osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>When assessing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, any additives in the solution must also be considered.  </p>
<p>The effects of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may require immediate medical attention and treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_inv-4292a48b-7423-4ec0-b528-5f9c2c0938f5"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">As directed by a physician. Dosage, rate, and duration of administration are to be individualized and dependent upon the indication for use, the patient’s age, weight, concomitant treatment and clinical condition of the patient as well as laboratory determinations. </p>
<p>All injections in VIAFLEX Plus plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.</p>
<p>After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion.  Do not reconnect any partially used containers. </p>
<p>The infusion rate should not exceed the patient’s ability to utilize glucose in order to avoid <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p>As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">low weight</span> infants, because of the increased risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (See <a href="#i4i_pediatric_use_id_inv-156043e6-5067-45a5-9e26-a3a1bd5e3e39">PRECAUTIONS, Pediatric Use</a>).</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  Do not administer unless the solution is clear and the seal is intact. </p>
<p>When making additions to Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP, aseptic technique must be used.  Mix the solution thoroughly when additives have been introduced.  Do not store solutions containing additives.  </p>
<p>Additives may be incompatible with Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP.  As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition, by checking for a possible color change and/or the appearance of precipitates, insoluble complexes, or crystals.  Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP is appropriate. </p>
<p>The instructions for use of the medication to be added and other relevant literature must be consulted.  Additives known or determined to be incompatible should not be used.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_inv-28ffed7c-9255-4946-8896-eaafa0888bd2"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP in VIAFLEX Plus plastic containers is available as shown below:</p>
<a name="id_4d9d9339-19ca-4ee2-9429-c5bdf459b8d0"></a><table width="599">
<col width="13.7%">
<col width="12.9%">
<col width="23.9%">
<col width="49.6%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">Code</span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Size (mL)</span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top"><span class="Bold">Product Name</span></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">2B2224</td>
<td align="left" valign="top">1000</td>
<td align="left" valign="top">0338-0811-04</td>
<td align="left" valign="top">20 mEq/L Potassium<br>Chloride in Lactated<br>Ringer’s and 5%<br>Dextrose Injection, USP</td>
</tr>
</tbody>
</table>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-c8c40130-0b69-4898-a040-6f602a1aa963"></a><a name="section-10"></a><p></p>
<h1>DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER</h1>
<p class="First">For Information on Risk of <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">Air Embolism</span> – see <a href="#i4i_precautions_id_inv-3e4f0243-f82e-4195-a64c-1715a41f6fdc">PRECAUTIONS</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-e391b10f-9210-470e-8ecf-e29f3deca0a4"></a><a name="section-10.1"></a><p></p>
<h2>To Open</h2>
<p class="First">Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. If supplemental medication is desired, follow directions below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-2e8fd84d-566c-4c6c-bf63-c93fb4faea3c"></a><a name="section-10.2"></a><p></p>
<h2>Preparation for Administration</h2>
<ol>
<li>Suspend container from eyelet support.</li>
<li>Remove protector from outlet port at bottom of container.</li>
<li>Attach administration set. Refer to complete directions accompanying set.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-7e6bbf3c-5e97-479e-86e5-66b5ef54543b"></a><a name="section-10.3"></a><p></p>
<h2>To Add Medication</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-178a0fd6-52a1-4407-9ab0-ed02158d2e6d"></a><a name="section-10.3.1"></a><p></p>
<h3>To add medication before solution administration</h3>
<ol>
<li>Prepare medication site.</li>
<li>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</li>
<li>Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-9dceb1ff-9568-4a09-9a57-df3ca6471608"></a><a name="section-10.3.2"></a><p></p>
<h3>To add medication during solution administration</h3>
<ol>
<li>Close clamp on the set.</li>
<li>Prepare medication site.</li>
<li>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</li>
<li>Remove container from IV pole and/or turn to an upright position.</li>
<li>Evacuate both ports by squeezing them while container is in the upright position.</li>
<li>Mix solution and medication thoroughly.</li>
<li>Return container to in use position and continue administration.</li>
</ol>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_560e413c-a836-40e1-8f4d-529f32f0f7bf"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation<br></span>Deerfield, IL 60015 USA</p>
<p>Printed in USA</p>
<p>07-19-72-482<br>Rev. November 2013</p>
<p>Baxter, VIAFLEX, and PL 146 are trademarks <br>of Baxter International Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_aac1ec06-a577-4656-884a-79e749e5b1f2"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Representative Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05f326e6-10e4-4ceb-8a23-f53c592f00b8&amp;name=14e57ddb-471a-4740-baef-451d53dccefe-02.jpg"></div>
<p class="First">LOT</p>
<p>EXP</p>
<p><span class="Bold">2B2224<br>NDC 0338-0811-04<br>DIN 00786314</span></p>
<p><span class="Bold">20 mEq</span></p>
<p><span class="Bold">Potassium Chloride</span></p>
<p><span class="Bold">(20 mEq/L) Potassium Chloride in <br>Lactated Ringer's and 5% Dextrose <br>Injection USP</span></p>
<p><span class="Bold">1000 mL</span></p>
<p>EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP 600 mg <br>SODIUM CHLORIDE USP 310 mg SODIUM LACTATE 179 mg <br>POTASSIUM CHLORIDE USP 20 mg CALCIUM CHLORIDE USP pH <br>5.0 (3.5 TO 6.5) mEq/L SODIUM 130 POTASSIUM 24 <br>CALCIUM 3 CHLORIDE 129 LACTATE 28 HYPERTONIC <br>OSMOLARITY 565 mOsmol/L (CALC) STERILE NONPYROGENIC <br>SINGLE DOSE CONTAINER <span class="Bold">NOT FOR USE IN THE TREATMENT OF <br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span> ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH <br>PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE <br>ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE <br>INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS <br>CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS <br>PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE FOUND MUST NOT BE <br>USED IN SERIES CONNECTIONS DO NOT ADMINISTER <br>SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS SOLUTION IS <br>CLEAR Rx ONLY STORE UNIT IN MOISTURE BARRIER OVERWRAP AT <br>ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID <br>EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX PLUS CONTAINER</p>
<p>PL 146 PLASTIC</p>
<p>BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC</p>
<p>FOR PRODUCT INFORMATION 1-800-933-0303</p>
<p><span class="Bold"><span class="Italics">Baxter<br></span></span>BAXTER HEALTHCARE CORPORATION<br>DEERFIELD IL 60015 USA</p>
<p>MADE IN USA</p>
<p>DISTRIBUTED IN CANADA BY<br><span class="Bold">BAXTER CORPORATION</span><br>TORONTO ONTARIO CANADA</p>
<div class="Figure">
<img alt="Representative Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05f326e6-10e4-4ceb-8a23-f53c592f00b8&amp;name=14e57ddb-471a-4740-baef-451d53dccefe-03.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>2B2224X </p>
<p>14-1000 ML </p>
<p>VIAFLEX® CONTAINER </p>
<p>20 MEQ POTASSIUM CHLORIDE IN <br>LACTATED RINGER’S AND 5% DEX INJ USP </p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE </p>
<p>(17) YYMM00 (10) XXXXX </p>
<p>LOT <br>XXXXX </p>
<p>PRIMARY BAR CODE </p>
<p>(01) 50303380811040 </p>
<div class="Figure"><img alt="Representative Container Label 0338-0815-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05f326e6-10e4-4ceb-8a23-f53c592f00b8&amp;name=14e57ddb-471a-4740-baef-451d53dccefe-04.jpg"></div>
<p>LOT</p>
<p>EXP</p>
<p><span class="Bold">2B2244<br>NDC 0338-0815-04<br>DIN 00786322</span></p>
<p> 40 mEq </p>
<p><span class="Bold">Potassium Chloride</span></p>
<p><span class="Bold">(40 mEq/L) Potassium Chloride in <br>Lactated Ringer's and 5% Dextrose <br>Injection USP</span></p>
<p><span class="Bold">1000 mL</span></p>
<p>EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP 600 mg <br>SODIUM CHLORIDE USP 328 mg POTASSIUM CHLORIDE USP<br>310 SODIUM LACTATE 179 mg 20 mg CALCIUM CHLORIDE USP <br>pH 5.0 (3.5 TO 6.5) mEq/L SODIUM 130 POTASSIUM 44 <br>CALCIUM 3 CHLORIDE 149 LACTATE 28 OSMOLARITY <br>605 mOsmol/L (CALC) HYPERTONIC MAY CAUSE VEIN DAMAGE <br>STERILE NONPYROGEIC SINGLE DOSE CONTAINER <span class="Bold"><br>NOT FOR USE IN THE TREATMENT OF  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span><br>ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH <br>PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE <br>ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE <br>INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS <br>CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS <br>PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE FOUND MUST NOT BE <br>USED IN SERIES CONNECTIONS DO NOT ADMINISTER <br>SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS SOLUTION IS <br>CLEAR Rx ONLY STORE UNIT IN MOISTURE BARRIER OVERWRAP AT <br>ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID <br>EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX PLUS CONTAINER</p>
<p>PL 146 PLASTIC</p>
<p>BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC</p>
<p>FOR PRODUCT INFORMATION 1-800-933-0303</p>
<p><span class="Bold"><span class="Italics">Baxter logo<br></span></span>BAXTER HEALTHCARE CORPORATION<br>DEERFIELD IL 60015 USA</p>
<p>MADE IN USA</p>
<p>DISTRIBUTED IN CANADA BY<br><span class="Bold">BAXTER CORPORATION</span><br>TORONTO ONTARIO CANADA</p>
<div class="Figure"><img alt="Representative Carton Label 0338-0815-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05f326e6-10e4-4ceb-8a23-f53c592f00b8&amp;name=14e57ddb-471a-4740-baef-451d53dccefe-05.jpg"></div>
<p>2B2244X </p>
<p>14-1000 ML </p>
<p>VIAFLEX® CONTAINER </p>
<p>40 MEQ POTASSIUM CHLORIDE IN <br>5% DEXTRS AND LACTATED RINGER'S INJ </p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE </p>
<p>(17) YYMM00 (10) XXXXX </p>
<p>LOT <br>XXXXX </p>
<p>PRIMARY BAR CODE </p>
<p>(01) 50303380815048 </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POTASSIUM CHLORIDE IN LACTATED RINGERS AND DEXTROSE 		
					</strong><br><span class="contentTableReg">dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0811</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROSE MONOHYDRATE</strong> (ANHYDROUS DEXTROSE) </td>
<td class="formItem">DEXTROSE MONOHYDRATE</td>
<td class="formItem">5 g  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION and CHLORIDE ION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">600 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM LACTATE</strong> (SODIUM CATION and LACTIC ACID) </td>
<td class="formItem">SODIUM LACTATE</td>
<td class="formItem">310 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION and CHLORIDE ION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">179 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCIUM CHLORIDE</strong> (CALCIUM CATION and CHLORIDE ION) </td>
<td class="formItem">CALCIUM CHLORIDE</td>
<td class="formItem">20 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0811-04</td>
<td class="formItem">1000 mL in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019367</td>
<td class="formItem">04/05/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POTASSIUM CHLORIDE IN LACTATED RINGERS AND DEXTROSE 		
					</strong><br><span class="contentTableReg">dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0815</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROSE MONOHYDRATE</strong> (ANHYDROUS DEXTROSE) </td>
<td class="formItem">DEXTROSE MONOHYDRATE</td>
<td class="formItem">5 g  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION and CHLORIDE ION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">600 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM LACTATE</strong> (SODIUM CATION and LACTIC ACID) </td>
<td class="formItem">SODIUM LACTATE</td>
<td class="formItem">310 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION and CHLORIDE ION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">328 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCIUM CHLORIDE</strong> (CALCIUM CATION and CHLORIDE ION) </td>
<td class="formItem">CALCIUM CHLORIDE</td>
<td class="formItem">20 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0815-04</td>
<td class="formItem">1000 mL in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019367</td>
<td class="formItem">04/05/1985</td>
<td class="formItem">10/27/2010</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">ANALYSIS(0338-0811, 0338-0815), MANUFACTURE(0338-0811, 0338-0815), LABEL(0338-0811, 0338-0815), PACK(0338-0811, 0338-0815), STERILIZE(0338-0811, 0338-0815)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>14e57ddb-471a-4740-baef-451d53dccefe</div>
<div>Set id: 05f326e6-10e4-4ceb-8a23-f53c592f00b8</div>
<div>Version: 4</div>
<div>Effective Time: 20140425</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
